Hims & Hers Health jumped 7% on Thursday after the telehealth company announced an expansion of its platform to include weight loss treatments from Eli Lilly.
Hims & Hers Health, Inc., HIMS
Clinicians using the Hims & Hers platform can now prescribe Zepbound vials, KwikPen, and Foundayo. Prescriptions can be filled through the LillyDirect pharmacy, with self-pay pricing options available to Hims & Hers customers.
The move gives licensed providers on the platform a direct route to connect patients with FDA-approved GLP-1 therapies.
This latest deal follows a partnership announced last month with Novo Nordisk. That tie-up gave Hims & Hers customers access to Wegovy injections and oral treatments.
Together, the two deals mark a clear pivot in the company’s U.S. weight loss strategy. The company says the shift is driven by growing demand and changing market dynamics around GLP-1 medications.
The weight loss program also includes 24/7 care team access, personalized nutrition plans, clinical follow-ups, and peer support through its Weight Loss community.
Hims & Hers says its goal is to offer a wide range of treatment options tailored to individual medical history and health goals.
The stock got a second boost on Friday when J.P. Morgan initiated coverage with an “Overweight” rating and a $35 price target.
Analysts pointed to the Novo Nordisk partnership as a turning point for the company’s weight-loss segment, saying it reduces regulatory risk tied to compounded GLP-1 offerings while opening access to branded treatments.
J.P. Morgan estimates HIMS is on track to exceed 100,000 monthly Wegovy prescriptions, which would translate to an annual revenue run rate of roughly $350–$400 million from that product alone.
The bank also flagged peptide-based therapies as a long-term growth opportunity. With U.S. regulators considering approval for mass compounding of several peptides, Hims & Hers’ in-house manufacturing could give it an early advantage.
J.P. Morgan projects revenue growing from $2.3 billion in 2025 to over $3.2 billion by 2027, with EBITDA hitting $414 million. The company itself is targeting more than 20% annual revenue growth through 2030.
Revenue growth is expected to reaccelerate in the second half of 2026 as new specialties scale up and branded offerings improve customer economics.
That said, risks remain. The stock is one of the most shorted in its category. Investor concerns include slowing growth, rising customer acquisition costs, and competition from Amazon and telehealth rival Ro.
J.P. Morgan acknowledged those risks but said the current valuation doesn’t fully reflect the company’s growth potential.
HIMS serves approximately 2.5 million subscribers across weight loss, sexual health, and dermatology. Its vertically integrated model — covering medical providers, pharmacies, and manufacturing — was highlighted by J.P. Morgan as a key competitive edge.
At the time of writing, Novo Nordisk (NVO) was up 5.53% and Eli Lilly (LLY) was down 2.84% on the day.
The post Hims & Hers (HIMS) Bets Big on Branded GLP-1s — J.P. Morgan Likes What It Sees appeared first on CoinCentral.
